ClinicalTrials.gg
CompletedNCT02435277Updated Jan 17, 2018Results posted

An Extension Protocol to Evaluate Dose Comparisons of Leucine-Metformin Combinations in Type 2 Diabetic Patients

A Phase 2 interventional study of Low Metformin and Mid Metformin in Type 2 Diabetes Mellitus, sponsored by NuSirt Biopharma. Completed at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-01-17.

Sponsored by NuSirt Biopharma · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 293 studies testing metformin in Diabetes Mellitus, Type 2 — 17 open to participants now, 22 under way, 2 of them phase 3. Metformin · Diabetes Mellitus, Type 2.

Enrollment
195th of 287
50 · median 100
Started
2014
with 15 others
Phase 2
23 of 293
3 open now
Registered
200th of 293
by date

Among the 293 studies testing metformin in Diabetes Mellitus, Type 2, this one is the 195th largest by enrollment of the 287 interventional ones that give a count, is one of 16 that started in 2014, is one of 23 in phase 2, and was the 200th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

17 of the 293 studies testing metformin in Diabetes Mellitus, Type 2 are open now, in 7 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About metformin

Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 293 studies testing metformin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Study NS-0100-01E is an extension of Study NS-01-0100 designed to assess safety and longer term effect (i.e., additional 8 weeks) of various fixed-dose leucine and metformin combinations (NS-0100) versus standard metformin monotherapy on glycemic control in subjects with type 2 diabetes using HbA1c as the primary endpoint.

Read the detailed description

This is a randomized, 8-week, extension of Study NS-0100-01, to evaluate the effect of various fixed-dose (FDC) combinations of leucine and metformin compared to standard metformin monotherapy on glycemic control.

Subjects meeting all inclusion criteria and no exclusion criteria for the extension study, including completion of the 4-week treatment period of Study NS-0100-01 [Day 28/Visit 7]), will be eligible to enroll into the extension. During participation in the extension, subjects will continue to receive their assigned treatment based upon the randomization that occurred on Day 1 (Visit 4) of Study NS-0100-0. The study will include a total of 3 visits: Visit 1E (Day 28/Visit 7 of Study NS-0100-01), Visit 2E (Day 56/Week 8), and Visit 3E (Day 84/Week 12). Key assessments at Visit 2E and Visit 3E include HbA1c, fasting plasma glucose, and plasma insulin. In addition, 3-hour standardized meal tests will be performed on Day 28 (as part of the Study Termination [Visit 7] procedures of Study NS-0100-01 prior to enrolling into the extension) and at Study Termination for the extension (Visit 3E [Day 84/Week 12]).

03

Conditions studied

  • Type 2 Diabetes Mellitus

Keywords

  • Diabetes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has completed Study NS-0100-01, including all procedures required at Study Termination (Day 28/Visit 7) without major protocol deviations
  2. Is male, or female and, if female, meets all of the following criteria:

    • Not breastfeeding
    • or negative pregnancy test result (human chorionic gonadotropin, beta subunit [β-hCG]) at Screening (Visit 1) (not required for hysterectomized females)
    • If of (including perimenopausal women who have had a menstrual period within one year) and sexually active, must practice and be willing to continue to practice appropriate (defined as a method which results in a low failure rate, i.e., less than 1% per year, when used consistently and correctly, such as double barrier methods [male condom with spermicide, with or without cervical cap or diaphragm], implants, injectables, oral contraceptives [must have been using for at least the last 3 months], some intrauterine contraceptive devices, tubal ligation, or a vasectomized partner) during the entire duration of the study.
  3. Is able to read, understand, and sign the forms (ICF) and if applicable, an authorization to use and disclose protected health information form (consistent with health insurance portability and accountability act of 1996 [HIPAA] legislation), communicate with the investigator, and understand and comply with protocol requirements.

Exclusion criteria

Exclusion Criteria:

Subjects who meet any of the following criteria will be excluded from the study.

  1. Is undesirable as a study participant as judged by the investigator (e.g., exhibited poor compliance during Study NS-0100-01)
  2. Is expected to require treatment, or if currently on a stable dose, changes to their regimen of the following medications:

    • Lipid-lowering agents
    • Anti-hypertensive medications
    • Thyroid replacement therapy
    • Non-steroidal anti-inflammatory agents
  3. Is expected to require or undergo treatment with any of the following medications:

    • Antidiabetes medications (with the exception of study medication [i.e., metformin])
    • Oral or parenteral .
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Low Metformin

    3 capsules BID with each capsule containing 366.7 mg L-Leucine and 41.7 mg of metformin

    Drug: Low Metformin

  • Experimental
    Mid Metformin

    3 capsules BID with each capsule containing 366.7 mg L-Leucine and 83.3 mg of metformin

    Drug: Mid Metformin

  • Experimental
    High Metformin

    3 capsules BID with each capsule containing 366.7 mg L-Leucine and 166.7 mg of metformin

    Drug: High Metformin

  • Active comparator
    Metformin Monotherapy

    3 Capsules BID each containing 283.3 mg of metformin BID (1,700 mg/Day) at Day 14.

    Drug: Metformin

Interventions

  • DrugLow Metformin

    1100 mg L Leucine in combination with 125 mg of Metformin BID

    Also known as: Metformin, L-Leucince, Leucine

  • DrugMid Metformin

    1100 mg L Leucine in combination with 250mg Metformin BID

    Also known as: Metformin, Leucine, L-Leucine

  • DrugHigh Metformin

    1100 mg of L Leucine in combination with 500 mg Metformin BID

    Also known as: Metformin, Leucine, L-Leucine

  • 500 mg Metformin BID until day 14 with dose escalation at day 14 to 850 mg Metformin BID

    Also known as: Metformin, Leucine, L-Leucine

06

What researchers measure

Primary outcomes

  1. Change in HbA1c Levels in Patient Receiving the Various Doses of Leucine and Metformin Combinations

    Change in HbA1c from Baseline (Day 1/Visit 1) of Study NS-0100-01 to Week 12 (Day 84/Visit 3E) in subjects receiving various fixed-dose combinations of leucine and metformin compared to standard metformin monotherapy.

    Time frame: Baseline and 12 weeks

Secondary outcomes

  1. Change in Fasting Plasma Glucose

    Change in fasting plasma glucose from Baseline (Day 1/Visit 1) of Study NS-0100-01 to Week 12 (Day 84/Visit 3E). Based on the pre-specified mixed model inferential statistical analysis, there was an apparent dose-dependent relationship for the mean decrease from baseline in fasting plasma glucose for the fixed dose leucine amd metformin combination treatments A, B and C.

    Time frame: Baseline and 12 weeks

07

Results

Posted Dec 18, 2017

Participant flow

Study NS-0100-01E was a randomized, double-blind 8-week extension of Study NS-0100-01 to evaluate the effect of various fixed-dose combinations of leucine and metformin compared to standard metformin monotherapy on glycemic control.

Participant flow — Overall Study
MilestoneFDC 125FDC 250FDC 500Control
Started12161111
Completed10151111
Not completed2100
Withdrew: Adverse event1100
Withdrew: Withdrawal by subject1000

Outcome measures

PrimaryChange in HbA1c Levels in Patient Receiving the Various Doses of Leucine and Metformin Combinations

Change in HbA1c from Baseline (Day 1/Visit 1) of Study NS-0100-01 to Week 12 (Day 84/Visit 3E) in subjects receiving various fixed-dose combinations of leucine and metformin compared to standard metformin monotherapy.

Time frame:
Baseline and 12 weeks
Reported as:
Mean · percent HbA1c
Change in HbA1c Levels in Patient Receiving the Various Doses of Leucine and Metformin Combinations
percent HbA1cFDC 125FDC 250FDC 500Control
Change in HbA1c Levels in Patient Receiving the Various Doses of Leucine and Metformin Combinations0.10 ± 0.756-0.12 ± 0.987-0.05 ± 0.807-0.83 ± 0.627
Statistical analysis
  • FDC 125 vs Control · ANCOVA · p = 0.0475 (Total daily dose is twice the respective dose, Pairwise Comparison using Control as the Reference Group)
  • FDC 250 vs Control · ANCOVA · p = 0.0912
  • FDC 500 vs Control · ANCOVA · p = 0.0458
SecondaryChange in Fasting Plasma Glucose

Change in fasting plasma glucose from Baseline (Day 1/Visit 1) of Study NS-0100-01 to Week 12 (Day 84/Visit 3E). Based on the pre-specified mixed model inferential statistical analysis, there was an apparent dose-dependent relationship for the mean decrease from baseline in fasting plasma glucose for the fixed dose leucine amd metformin combination treatments A, B and C.

Time frame:
Baseline and 12 weeks
Reported as:
Mean · mg/dL
Change in Fasting Plasma Glucose
mg/dLFDC 125FDC 250FDC 500Control
Change in Fasting Plasma Glucose-15.8 ± 22.2911.2 ± 22.37-4.3 ± 39.91-36.3 ± 45.47
Statistical analysis
  • FDC 125 vs Control · ANCOVA · p = 0.26 (Total daily dose is twice the respective dose Pairwise Comparison using Treatment D as the Reference Group)
  • FDC 250 vs Control · ANCOVA · p = 0.0083
  • FDC 500 vs Control · ANCOVA · p = 0.0317

Adverse events

Collected over 84 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FDC 1250/12 (0%)0/12 (0%)2/12 (16.7%)
FDC 2500/16 (0%)1/16 (6.3%)2/16 (12.5%)
FDC 5000/11 (0%)0/11 (0%)2/11 (18.2%)
Control0/11 (0%)0/11 (0%)1/11 (9.1%)
Most frequent serious events
Most frequent serious events
EventFDC 125FDC 250FDC 500Control
Chest PainCardiac disorders0/121/160/110/11
Most frequent other events
Showing 10 of 12
Most frequent other events
EventFDC 125FDC 250FDC 500Control
musculoskeletalMusculoskeletal and connective tissue disorders0/120/162/110/11
Respiratory dsordersRespiratory, thoracic and mediastinal disorders2/121/160/110/11
CoughGeneral disorders2/120/160/110/11
Gastric DisordersGastrointestinal disorders0/122/161/110/11
Upper Respiratory Tract InfectionRespiratory, thoracic and mediastinal disorders0/122/160/110/11
DiarrhoeaGeneral disorders0/121/160/111/11
EcchymosisGeneral disorders1/120/161/110/11
EndocrineEndocrine disorders1/121/160/110/11
HyperglycemiaEndocrine disorders1/121/160/110/11
FatigueGeneral disorders0/121/160/110/11

Baseline characteristics

Study NS-0100-01E was the extension of Study NS-01-0100 designed to assess safety and longer term effect (ie, additional 8 weeks) of various fixed-dose leucine and metformin combinations (NS-0100) versus standard metformin monotherapy on glycemic control in subjects with type 2 diabetes.

Age, Categorical
Age, Categorical(Participants)FDC 125FDC 250FDC 500ControlTotal
<=18 years00000
Between 18 and 65 years10138940
>=65 years233210
Age, Continuous
Age, Continuous(years)FDC 125FDC 250FDC 500ControlTotal
Mean51.8 ± 10.8156.1 ± 8.2459.8 ± 9.0160.5 ± 8.7756.9 ± 9.52
Sex: Female, Male
Sex: Female, Male(Participants)FDC 125FDC 250FDC 500ControlTotal
Female886729
Male485421
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)FDC 125FDC 250FDC 500ControlTotal
Hispanic or Latino582419
Not Hispanic or Latino789731
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)FDC 125FDC 250FDC 500ControlTotal
American Indian or Alaska Native01001
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American225413
White10136736
More than one race00000
Unknown or Not Reported00000
Weight
Weight(kg)FDC 125FDC 250FDC 500ControlTotal
Mean93.343 ± 19.017991.314 ± 18.766487.497 ± 21.225990.500 ± 18.416390.782 ± 18.8230
Body Mass Index (BMI)
Body Mass Index (BMI)((kg/m^2)FDC 125FDC 250FDC 500ControlTotal
Mean33.298 ± 4.495231.647 ± 6.324228.627 ± 4.519532.677 ± 5.380831.606 ± 5.4597
Fasting Plasma Glucose
Fasting Plasma Glucose(mg/dL)FDC 125FDC 250FDC 500ControlTotal
Mean173.5 ± 31.13150.5 ± 26.78179.2 ± 36.04177.1 ± 53.67168.2 ± 38.00

2 further baseline measures are reported on the registry.

08

Study locations

9 sites
  • Catalina Research Institute
    Chino, California 91710, United States
  • Palm Beach Research
    Palm Beach, Florida 33409, United States
  • Meridien Research
    Tampa, Florida 33606, United States
  • River Birch Research Alliance
    Blue Ridge, Georgia 3051313, United States
  • Meridian Research
    Savannah, Georgia 31406, United States
  • Streling Research Group
    Cincinnati, Ohio 45219, United States
  • Medical Research South
    Charleston, South Carolina 29407, United States
  • Meharry Medical College
    Nashville, Tennessee 37208, United States
  • Vanderbilt University Medical Center, Diabetes, Endocrinology, and Metabolism
    Nashville, Tennessee 37232, United States
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2014, a primary completion of Sep 2015 and a completion of Jan 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2017, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2015
First posted
May 6, 2015
Start
Oct 2014
Primary completionActual
Sep 2015
CompletionActual
Jan 2016
Results first posted
Dec 18, 2017
Last update
Jan 17, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 17, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02435277
Lead sponsor
NuSirt Biopharma
Responsible party
Sponsor
First posted
May 6, 2015
Start date
Oct 2014
Primary completion
Sep 2015
Completion
Jan 2016
Results posted
Dec 18, 2017
Last update
Jan 17, 2018

Study contacts

Orville Kolterman, MD
study chair · Pharmapace

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metformin

Start the discussion